logo-loader
RNS
viewGlaxoSmithKline PLC

GlaxoSmithKline PLC - Publication of GSK 2019 Form 20-F

RNS Number : 3525F
GlaxoSmithKline PLC
09 March 2020
 

 

GlaxoSmithKline plc
Annual Report 2019 on Form 20-F

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 06 March 2020 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2019. GSK's 2019 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk.

A hard copy version of the GSK 2019 Annual Report, together with the Notice of Annual General Meeting will be available on or about 23 March 2020.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2020, free of charge, by either:

(i)      writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);

(ii)      writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 800 990 1135 (US toll free) or +1 651 453 2128 (outside the US); or

(iii)     contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

Victoria Whyte
Company Secretary
06 March 2020

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2019.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCKKABDDBKBONK

Quick facts: GlaxoSmithKline PLC

Price: 1672.8442

Market: LSE
Market Cap: £83.98 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE